Global and Chinese Monoclonal Antibody Industry Report 2013
DUBLIN, Dec. 5, 2013 /PRNewswire/ – Research and Markets (http://www.researchandmarkets.com/research/4pvg4q/global_and) has announced the addition of the “Global and Chinese Monoclonal Antibody Industry Report, 2013″ report to their offering.
In recent years, the monoclonal antibody market around the globe has witnessed substantial growth, and the CAGR of market scale during 1997-2011 has reached 44% approximately. It is predicted that the global monoclonal antibody market scale will reach USD78 billion in 2012. Meanwhile, monoclonal antibody is also a key major source of blockbuster drugs.
Due to the features as high technical threshold, large capital demand and high rate of return, the international pharmaceutical giants (including Roche, Johnson & Johnson, Abbvie, Amgen, Novartis, etc.) are still accelerating the research and industrialization of monoclonal antibody agents through M&A or cooperation on the basis of existing monoclonal antibody products.
Global and China Monoclonal Antibody Industry Report 2013 mainly involves the following contents:
-- Development status, market scale, competitive pattern and development forecast, etc. of monoclonal antibody industry around the globe -- Development status, market scale, competitive pattern and development forecast, etc. of monoclonal antibody industry in China -- Operation, monoclonal antibody business, development in China, R&D status, etc. of 6 monoclonal antibody enterprises around the globe and 10 enterprises in China
Key Topics Covered:
1. Overview of Monoclonal Antibody Industry
1.3 Technological Development
2. Development of Global Monoclonal Antibody Industry
2.1 Development Situation
2.2 Market Scale
2.3 Competitive Pattern
2.4 Development Prospect and Forecast
3. Monoclonal Antibody Industry in China
3.1 Development Situation
3.2 Market Scale
3.3 Market Segments
3.4 Competitive Pattern
3.5 Development Prospect
4. Key Enterprises of Monoclonal Antibody Agents Overseas
5. Key Enterprises of Monoclonal Antibody Agents in China
-- AbbVie -- Amgen -- Beijing Biotech Pharmaceutical -- Beijing SL Pharmaceutical -- Chengdu Huasun Group -- Johnson & Johnson -- Merck -- NVS -- Roche Pharmaceuticals -- Shanghai Fosun Pharmaceutical -- Shanghai Lansheng States Kin Pharmaceutical -- Shanghai Medipharm Biotech -- Shanghai Yalian Antibody Pharmaceutical -- Shenzhen Main Luck Pharmaceuticals -- Yunnan Walvax Biotechnology -- Zhejiang Hisun Pharmaceutical
For more information visit http://www.researchandmarkets.com/research/4pvg4q/global_and.
Laura Wood , +353-1-481-1716, email@example.com
SOURCE Research and Markets